Nav: Home

Results with new bioresorbable stent (BRS) technologies reported at EuroPCR 2017

May 19, 2017

Paris, France: Promising results were reported in late-breaking trials with novel bioresorbable stent technologies at EuroPCR 2017, paving the way for ongoing developments in stents that are dissolved or reabsorbed after achieving vessel expansion in percutaneous coronary intervention procedures.

Researchers reported results with seven bioresorbable stent technologies:
  • Nine-month clinical and imaging outcomes of a novel ultra-high molecular weight poly-L-lactide BRS. A prospective multicenter international investigation: The RENASCENT II study.

Results from the prospective multicentre RENASCENT II study of the Amaranth Medical APTITUDE BRS stent, a novel ultra-high molecular weight poly-L-lactide BRS with a new, thinner strut (120 μm), reported no events at one year in 60 patients treated for single lesion coronary artery stenosis. Coronary artery imaging with optical coherence tomography (OCT) demonstrated excellent wall apposition and full, homogenous endothelial wall coverage, with no valleys and peaks between regions with struts and those without struts. "The results are very positive. The scaffold delivers a very low medium-term event rate and the stent favours good laminar flow in blood vessels," said lead author Antonio Colombo, from San Raffaele Scientific Institute, Milan, Italy, although he cautioned that the study was small.
  • Prospective, multicentre evaluation of the DESolve Novolimus-Eluting coronary BRS: imaging outcomes and four-year clinical and imaging results

The key imaging results from the DESolve Nx Study, a prospective registry including 126 patients, showed a mean lumen gain of 9% at six months, as measured by intravascular ultrasound (IVUS), and an angiographic late luminal loss (LLL) of 0.2mm. "This is a clinical breakthrough as no other BRS technology has been successful in achieving such impressive results and, at the same time, degrading in six months with near complete resorption (mass loss) in one year," said lead author Stefan Verheye, from ZNA Middelheim, Antwerpen, Belgium. He added that the 18-month and 36-month imaging data showed sustained efficacy and confirmed the degradation and complete resorption (mass loss) in one year. There were no late or very late definite or probable scaffold thromboses and no target lesion revascularisations from years two to four. Verheye concluded, "Early degradation and early resorption is not only an intuitive wish, it is a must for a BRS technology in order to succeed. Companies attempted but failed to achieve clinical effectiveness, primarily due to chronic recoil of their scaffolds. In an effort to resolve this issue, companies had to revert to much longer degradation and resorption profiles. The Elixir DESolve scaffold is the only technology to date to resolve the chronic recoil issue, as evidenced by the Nx trial data."
  • One-year clinical and multislice computer tomography results with a thin-strut poly-L-lactic acid-based sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease: MeRes-1 study

One-year results from the first-in-man MeRes-1 study of the safety and efficacy of the novel MeRes 100 scaffold in 108 patients with 116 de novo coronary artery lesions showed that the composite endpoint of cardiac death, myocardial infarction (MI) and ischaemia-driven target lesion revascularisation (ID-TLR) occurred in one patient (0.93%). There was no scaffold thrombosis. One-year computed tomography (CT) angiography demonstrated that all scaffolds were patent. Six-month quantitative coronary angiography showed a low rate of late lumen loss and no restenosis. Intravascular ultrasound and OCT analyses also gave favourable results, reported Ashok Seth, from Fortis Escort Heart Institute, New Delhi, India. He said, "The positive results of this study provide the basis for a larger, randomised trial against a second-generation metallic drug-eluting stent."

Data were also reported for the following studies, but results were not available to include in the press release:
  • The FANTOM II study: first report for the 12-month clinical outcomes of the Fantom sirolimus-eluting bioresorbable scaffold - Alexandre Abizaid, Instituto Dante Pazzanese, Sao Paulo, Brazil

  • Multicentre evaluation of a novel 120μm novolimus-eluting, fully coronary BRS: first report of six-month clinical and imaging endpoints - Alexandre Abizaid, Instituto Dante Pazzanese, Sao Paulo, Brazil

  • Short and midterm safety, clinical performance and multi-modality imaging results of the drug-eluting absorbable metal scaffold: combined data of the BIOSOLVE-II and BIOSOLVE-III trials - Michael Haude, Städtische Kliniken Neuss, Lukaskrankenhaus GmbH, Neuss, Germany

  • A first-in-man study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in patients with coronary artery disease (FUTURE-I): one-year clinical and imaging outcomes - Bo Xu, Fu Wai Hospital, Beijing, China
Contact information

Antonio Colombo
San Raffaele Scientific Institute
Milan, Italy

Stefan Verheye
ZNA Middelheim
Antwerpen, Belgium

Ashok Seth
Fortis Escorts Heart Institute
New Delhi, India

Michael Haude
Städtische Kliniken Neuss
Lukaskrankenhaus GmbH
Neuss, Germany

Alexandre Abizaid
Instituto Dante Pazzanese
Sao Paulo, Brazil

Xu Bo
Fu Wai Hospital
Beijing, China

Corresponding session

EuroPCR 2017 session: Tuesday 16 May 12.00-13.30, Hot Line/Late-breaking Trials, Coronary Interventions, Stents and Scaffolds; Room 351

Help for journalists to cover EuroPCR 2017
For any press-related inquiries, please contact:

EuroPCR Press Coordinator, Isabelle Uzielli

Register and attend EuroPCR 2017 as a journalist
Press registration for EuroPCR is open to accredited journalists, free of charge.
Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press go to

EuroPCR press releases
EuroPCR press releases can be found at

Attend press briefings
For the press briefing schedule check

EuroPCR abstracts
Abstracts are available online at

Notes to Editors
What is EuroPCR?
EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional cardiovascular medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 11,500 participants every year, PCR organises annual courses in Singapore, London UK, Dubai EAU, Johannesburg RSA, Milan Italy, Chengdu China and Tokyo Japan.

For further information on EuroPCR, PCR London Valves, PCR Peripheral, PCR-CIT China Chengdu Valves, GulfPCR-GIM, AsiaPCR, AfricaPCR, PCR Tokyo Valves, and all PCR activities, please contact: Célia Vilà:

For more information, please visit: and follow us on Twitter using the hashtag #EuroPCR


Related Coronary Artery Disease Articles:

Waist size, not body mass index, may be more predictive of coronary artery disease
For years, women have been told that weight gain could lead to heart disease.
Diagnosis of coronary artery disease improved by deep learning analysis of SPECT MPI
A multicenter international study has demonstrated that diagnosis of obstructive coronary artery disease can be improved through deep learning analysis of SPECT myocardial perfusion imaging.
Women with coronary artery wall thickness at risk for heart disease
The thickness of the coronary artery wall as measured by MRI is an independent marker for heart disease in women, according to a new study.
SPIE journal reports advances in use of 3D models in assessing coronary artery disease
In an article published in SPIE's Journal of Medical Imaging (JMI), researchers announce critical advances in the use of 3D-printed coronary phantoms with diagnostic software, further developing a non-invasive diagnostic method for Coronary Artery Disease (CAD) risk assessment.
E-cigarettes linked to heart attacks, coronary artery disease and depression
Concerns about the addictive nature of e-cigarettes -- now used by an estimated 1 out of 20 Americans -- may only be part of the evolving public health story surrounding their use, according to data being presented at the American College of Cardiology's 68th Annual Scientific Session.
Is guideline-recommended therapy for coronary artery disease more likely in Medicare Advantage?
Medicare Advantage is Medicare's managed-care alternative to traditional fee-for-service Medicare.
Cleveland Clinic genetic analysis links obesity with diabetes, coronary artery disease
A Cleveland Clinic genetic analysis has found that obesity itself, not just the adverse health effects associated with it, significantly increases the risk of Type 2 diabetes and coronary artery disease.
Early depression diagnosis is deadly serious for patients with coronary artery disease
While clinicians caring for patients with coronary artery disease may not always prioritize depression screening, an early diagnosis could be a matter of life and death.
Analysis of the 9p21.3 sequence associated with coronary artery disease
Before a conclusive link between the SDs and the cardiovascular diseases can be made, further analysis is required on the CAD interval in more patients with coronary artery disease and in the human population, using the TAR cloning technique in combination with qPCR or Droplet digital PCR developed in this work.
Percutaneous coronary intervention is a well-justified option also in severe coronary artery disease
The treatment of left main coronary artery disease by percutaneous coronary intervention is associated with a smaller risk of severe cardiovascular events than coronary artery bypass grafting in the weeks following surgery.
More Coronary Artery Disease News and Coronary Artery Disease Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.